์์ฆํธ๋ ์ค๋จ
**์์ฆํธ๋ ์ค๋จ(Aztreonam)**์ ๋ค์ํ ํธ๊ธฐ์ฑ ๋ฐ ํต์ฑ ํ๊ธฐ์ฑ ๊ทธ๋ ์์ฑ๊ท ์ ๋ํด ๊ฐ๋ ฅํ ํ์ฑ์ ๋ํ๋ด๋ ๋ชจ๋ ธ๋ฐํ๊ณ ์ฃผ์ฌ์ฉ ํญ์์ ์ ๋๋ค. * **ํญ๊ท ์คํํธ๋ผ:** ์ํธ๋ก๋ฐํฐ, ์ํ ๋ก๋ฐํฐ, ๋์ฅ๊ท , ํด๋ ๋ธ์์๋ผ, ํ๋กํ ์ฐ์ค, ์๋๋ชจ๋์ค ๋ฐ ์ธ๋ผํฐ์์ ๋งค์ฐ ํจ๊ณผ์ ์ ๋๋ค. * **์์ ์์ :** ๊ทธ๋ ์์ฑ๊ท ์ด๋ ํ๊ธฐ์ฑ ์ธ๊ท ์ ๋ํด์๋ ์์์ ํจ๋ฅ์ด **์์ต๋๋ค**. * **์์์ ์ ์ฉ์ฑ:** ์๋ฏธ๋ ธ๊ธ๋ฆฌ์ฝ์ฌ์ด๋๋ ํ๋ฃจ์ค๋กํด๋๋ก ๊ณ ์ฝ๋ฌผ์ด ํจ๊ณผ๊ฐ ์๊ฑฐ๋ ์๋์ ๊ธ๊ธฐ(์: ์ ๋ ์ฑ ์ฐ๋ ค)๊ฐ ์๋ ์ค์ฆ ๊ทธ๋ ์์ฑ๊ท ๊ฐ์ผ์ ์ข ์ข ๊ณ ๋ ค๋ฉ๋๋ค. * ์กฐ์ง ์นจํฌ๋ ฅ์ด ์ฐ์ํ๊ณ ๋ ์ฑ ๊ฐ๋ฅ์ฑ์ด ๋ฎ์ง๋ง, ์์ํ ๋์ ๋๋ฌผ์ ๋ํ ์์ ๊ฒฝํ ๋ฐ ์ฝ๋ํ์ ๋ฐ์ดํฐ๋ ์์ง ์ ํ์ ์ ๋๋ค.
์์ฉ ๊ธฐ์ : Aztreonam is a **bactericidal** antibiotic. * It selectively binds to **penicillin-binding protein-3 (PBP-3)** in susceptible bacteria. * Binding to PBP-3 โ **inhibits bacterial cell wall synthesis** โ results in cell lysis and death. * It is highly stable against the hydrolytic effects of bacterial **beta-lactamases** and, unlike many other beta-lactam antibiotics, does not induce beta-lactamase activity. * **Synergy:** Can exhibit synergistic effects against *Pseudomonas aeruginosa* and other gram-negative bacilli when used concurrently with aminoglycosides.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Serious gram-negative infections ยท 30 mg/kg ยท IM or IV ยท q6-8h ยท Anecdotal dosing suggestion based on the human pediatric dose. Aztreonam has a shorter half-life in dogs but is about half as bound to plasma proteins compared to humans.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Documented severe hypersensitivity to aztreonam
์ด์๋ฐ์
- Hypersensitivity reactions
- Gastrointestinal effects (bacterial overgrowth, pseudomembranous colitis, diarrhea)
- Pain and/or swelling after IM injection
- Phlebitis after IV administration
- Transient increases in liver enzymes, serum creatinine, and coagulation indices
์ฝ๋ฌผ ์ํธ์์ฉ
- Probenecid ยท Can reduce the renal tubular secretion of aztreonam, thereby maintaining higher systemic levels for a longer period of time. This potential 'beneficial' interaction requires further investigation in veterinary patients.
๋ชจ๋ํฐ๋ง
- Clinical efficacy
- Signs of toxicity or adverse effects
- Renal and hepatic function in compromised patients
๊ณผ์ฉ๋
There is little reason for concern in patients with adequate renal function. The IV LD50 for mice is 3.3 g/kg. Hemodialysis or peritoneal dialysis may be used to clear aztreonam from the circulation.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.